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trategies for diagnosis and treatment of acute febrile illness in
sia
. Suputtamongkol
Mahidol University, Bangkok, Thailand
Acute fever associated with multi-systems illness is a common
eature of several infections endemic in South-east Asia, includ-
ng malaria, dengue, scrub typhus, and leptospirosis. Malaria and
engue infectionmustbe initially excluded inall patientspresented
ith this syndrome. The lack of sensitive and rapid methods for
he laboratory conﬁrmation of a tentative diagnosis has been an
mportant problem.
Physician in the tropic should aware that malaria, dengue infec-
ion, rickettsioses, and leptospirosis are major causes of acute
ndifferentiated fever. Travelers to endemic areas are also at risk
f these infections. Early recognition and appropriate treatment
educe morbidity and mortality.
Doxycycline would usually be an appropriate initial antimicro-
ial treatment for individual with suspected either rickettsioses or
eptospirosis. Azithromycin could be considered as an alternative
reatment when ever doxycycline allergy is suspected.
In this presentation the outline of common causes of acute
ndifferentiated febrile illness among indigenous population and
nternational travelers returned fromSouth-eastAsia, and theman-
gement of these patients will be discussed.
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pidemiology, clinical manifestations, and diagnostic chal-
enges of pediatric tuberculosis
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Childhood Tuberculosis accounts for nearly 10% of all cases.
ts proportion varies from 5% in high income countries to 39% in
ow-and-middle income countries. Precise estimates are unavail-
ble due to lack standard case-deﬁnition, limited resources for
onﬁrmation of diagnosis and inconsistent surveillance data. Pedi-
tric Tuberculosis is considered as a sentinel event indicating
ecent transmission. Thus proportion of pediatric tuberculosis is
igh in countries where adult epidemic is poorly controlled and
an be used as an indicator to measure tuberculosis control.nfectious Diseases 16S (2012) e2–e157
Epidemiologically, children seldom contribute to disease transmis-
sion, as they tend todeveloppauci-bacillarydisease and less tussive
than the adults.
After primary infection, time until disease manifests and
symptoms vary according to age. Generally the symptoms are non-
speciﬁc and up to 50% may be asymptomatic. Tuberculin skin test
conversion occurs fairly quickly in 6-8 weeks. Intra-thoracic lymph
node disease (peri-hilar or paratracheal) which is radiological hall-
mark of primary infection is most common under ﬁve years of age
and occurs in 8-12 weeks. Pleural and pericardial effusions are
rare but occur after ﬁve years of age. Adult-type disease occurs
among adolescents 6-12 months after primary infection. HIV and
drug resistance have not only caused resurgence but also changed
in clinical presentation. Widespread BCG vaccination has reduced
Miliary and Meningeal Tuberculosis but disseminated and lymph
node Tuberculosis are rising due to HIV.
Diagnosis of childhood Tuberculosis poses myriad problems.
The classical triad of 1) exposure to an adult index case, (2) a posi-
tive tuberculin skin test, and (3) the presence of suggestive signs on
chest radiograph, has limited value in high burden countrieswhere
exposure to infection is very common. Studies about point scoring
systems, anddiagnostic algorithms, lackeduniformcasedeﬁnitions
and culture were not done as gold standard for diagnosis. Sputum
examination which is used as gold standard for adults is not appli-
cable for children. Culture has limited role since facilities for culture
are unavailable or growth is not found in all cases. Improved cul-
ture techniques, serodiagnosis, and nucleic acid ampliﬁcation are
promising but higher cost and lack of technical expertise hinder
their implementation in resource-limited settings.
http://dx.doi.org/10.1016/j.ijid.2012.05.159
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The major challenge of pediatric pulmonary TB (PPTB) is estab-
lishing an accurate diagnosis. Less than 15% of cases are sputum
AFB smear positive and culture yields are 30-40%. Induced sputum,
nasopharyngeal aspirate, earlymorning gastric aspiration or lavage
can give a better yield. Culture on Lowenstein-Jensen medium is
considered to be gold standard; however, liquid culture systems
(BACTEC andMGIT) aremore rapid and sensitive to diagnose active
TB and drug susceptibility. MODS assay is faster than solid culture
with simultaneousDSTand is inexpensive.Nevertheless, it requires
trained personnel, is labour intensive and lacks information for
children.
NAATs like line probe assay, Genotype MTBDRplus, GeneXpert
device, TB-LAMP for diagnosing active TB and DST are fast, robust,
fully automated, easy to use and easy for interpretation. The Geno-
Type MTBDRplusis the best known of these assays. However, the
tests are very expensive to be utilised in low- and middle income
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ountries and moreover, are not accurate enough for routine diag-
osis and needs further validation in children. Prevention of the
rogression of dormant infection plays an important role in TB con-
rol; it is performed by contact tracing using DNA ﬁngerprinting
mostly restriction fragment length polymorphism analysis [RFLP])
n both developed and less developed countries.
Serum-based antibody assays offer advantages of easy specimen
ollection and rapidity, although not sensitive or speciﬁc enough
or clinical use. Tests developed using combinations of antigens
rom proteonomics approach appear promising. Upcoming tests
ased on detection of antigens, such as lipoarabinomannan in urine
r serum samples, and cutaneous response to transdermal appli-
ation of mbp64 need further validation in children. Detection of
nterferon –  release assay have not shown any major advantage
ver Tuberculin Skin Test (TST) in terms of sensitivity and speci-
city and are more expensive. T-SPOT may discriminate between
on-TBmycobacterial diseases in children in settingswith low inci-
enceof TB;however, their role indetectionof TB inHIV-infectedor
alnourished childrenneeds further research. Reﬁnement of exist-
ng tools, development and testing of new tools, better laboratory
nfrastructure and dedicated national policy are urgently required
o improve diagnosis and treatment of PPTB in resource-poor coun-
ries.
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Pediatric tuberculosis which is considered as pauci-bacillary
s given low priority in Tuberculosis control. In resource-limited
ettings national TB control programmes focus on infectious spu-
um smear-positive cases. As result of this neglect pediatric
B is often under-diagnosed, under-treated and under-reported.
ontact-tracingwhich is routinelydone inhigh-incomecountries is
ot done in resource-limited countries. This has resulted in delayed
etection of tuberculosis among child contacts. Current standard-
zed reporting systemdoes not include indicators reﬂecting service
elivery to children.
Achieving treatment success in children relies on prompt diag-
osis and treatment initiation,with appropriate treatment regimen
weigh-based doses) and support for treatment adherence. An
mportant development in treatment of pediatric tuberculosis is
evised dosage guidelines recommending increased dosages of
rst-line drugs. But as yet no appropriate ﬁxed-dose combina-
ions and child-friendly formulations are consistent with the new
uidelines, treatmentproviders are struggling toprovidenewdoses
hrough complex interim dosing recommendations which resulted
n delayed implementation of new guidelines. The new guidelines
ave clariﬁed the role of Ethambutol in pediatric TB which wasnfectious Diseases 16S (2012) e2–e157 e65
questioned for its toxicity proﬁle, and also advised against the use
of streptomycin.
BCG vaccination only offers signiﬁcant protection against dis-
seminated disease and tuberculous meningitis in young children.
BCG vaccination is contraindicated in HIV-infected children and
those with other immune deﬁciencies. Development of novel vac-
cines with improved efﬁcacy and safety remains a major research
challenge. Children are frequently excluded fromdrug trials to pre-
vent risk posed to them and limited ﬁnancial return. However,
children should be included in the evaluation of novel TB drugs,
soon after the conclusion of initial safety and efﬁcacy studies. It is
essential to include children in safety and dose ranging studies and
also to develop child friendly formulations prior to product regis-
tration. Measures like tracing, screening and isoniazid preventive
therapy for eligible child contacts have been recommended but not
effectively implemented, since most TB programmes do not con-
sider themas priority. To tackle the emerging challenge of pediatric
tuberculosis changes and improvements in existing practices in
diagnosis and treatment are needed. Pediatric tuberculosis should
also be prioritized in National Tuberculosis Control Programs.
http://dx.doi.org/10.1016/j.ijid.2012.05.161
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Pitfall and challenges in clinical management of childhood
tuberculosis
K. Chokephaibulkit
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Children are more susceptible to TB and have higher risk of
extrapulmonary or severe forms of disease than in adults. Most
of TB in children acquired from household adults, and treatment
in adults help preventing disease in children. The common pitfalls
and challenges are:
- Diganosis: Because the clinical signs and symptoms of TB in chil-
dren are not speciﬁc and microbiologic yield is low, the diagnosis
of childhood TB is difﬁcult. Obtaining the specimens from sputum
is possible in young children and gastric aspiration is uncom-
fortable and mostly required hospitalization. None of the scoring
system is accurate. Clinical diagnosis and empirical treatment are
commonly practiced which may result in in-appropriate treat-
ment.
- Anti-tuberculous drugs: Pediatric formulation is limited avail-
able and for only rifampin. The recent pharmacokinetic study
suggested the need to increase recommended dose in children.
Recently, WHO recommended to increase INH from 5 to 10
mg/kg/day, rifampin from 10 to 15 mg/kg/day, pyrazinamide
from 25 to 35 mg/kg/day. Streptomycin is no longer recom-
mended in the ﬁrst line regimen.
- Adhering to treatment: DOT is needed but not available in most
resource-limited settings. Intermittent regimens (2-3 doses per
week) may help adherence but may reduce efﬁcacy and not rec-
ommend in HIV-infected children.
- Drug resistance: The drug susceptibility results are mostly
unavailable in children. Most of drug resistance cases were
